Sunday January 08, 2012

NeuVax E-75 Cancer Vaccine Halves Recurrence Rate

A vaccine discovered by a team of scientists from the US Army has proven successful in reducing the recurrence of cancer in patients participating in the clinical trials. The vaccine is called E-75 or NeuVax and will be undergoing expanded testing on 300 patients worldwide. If the tests are successful, a significant number of cancer patients could significantly benefit from the research.

E-75 works by using the patient’s own immune system to battle cancer, training it to be familiar with a common protein found on cancerous cells